Take that, Kleinschnitz!https://www.sciencealert.com/long-covid-seems-to-be-a-brain-injury-scientists-discover[*quote*]
Long COVID Seems to Be a Brain Injury, Scientists Discover16 February 2024
By David Nield
Series of brain scan images (Tek Image/Science Photo Library/Getty Images)
Some form of brain injury could be behind the symptoms reported by those with long COVID, according to a new study, and adapting tests and treatments to match could aid progress in tackling the condition.
Analyzing 203 patients hospitalized with COVID-19 or its associated symptoms, and comparing the results with 60 people without the infection, researchers noticed elevated levels of four brain injury biomarkers – key signs of biological change – in those infected with COVID-19.
What's more, two of those signs of brain injury persisted into the recovery phase, suggesting that they continue even after the COVID-19 infection has gone. Levels of these two biomarkers were even higher for people who also experienced neurological complications with COVID-19.
"Our study shows that markers of brain injury are present in the blood months after COVID-19, and particularly in those who have had a COVID-19-induced brain complication," says neuroscientist Benedict Michael from the University of Liverpool in the UK.
"This suggests the possibility of ongoing inflammation and injury inside the brain itself which may not be detected by blood tests for inflammation."
These brain complications associated with COVID-19 have ranged from mild (headaches) to potentially life-threatening (seizures, stroke, and encephalitis). As previous research has shown, the consequences can be long-lasting.
Michael and team think that abnormal responses by the body's immune system could be causing the signs of injury they're seeing. If we can find out more about these responses and how they're triggered, new treatments could be developed.
It's now clear that COVID-19 plays some role in impacting the nervous system, and in some cases this impact can continue for an extended period. This new study shows that the effects can be similar to brain injuries.
"The clinical characteristics of our participant cohorts, and the elevation in brain injury markers, provide evidence of both acute and ongoing neurological injury," write the researchers in their published paper.
The researchers are already hard at work following up on their study, looking at how the damage caused by COVID-19 and the associated inflammation might lead to cognitive problems and mental health issues further down the line.
It's thought that tens of millions of people are now living with long COVID in some form, and yet it's still not a condition that we know all that much about. Studies continue to try to spot patterns in its prevalence, which should eventually provide more clues as to how to combat it.
"This work may help set the stage for elucidating the possible underlying mechanisms of these complications," says immunologist Leonie Taams, from King's College London in the UK.
The research has been published in Nature Communications.
https://www.nature.com/articles/s41467-023-42320-4[*/quote*]
https://www.nature.com/articles/s41467-023-42320-4[*quote*]
Nature Communications
Open access
Published: 22 December 2023
Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses Benedict D. Michael, Cordelia Dunai, Edward J. Needham, Kukatharmini Tharmaratnam, Robyn Williams, Yun Huang, Sarah A. Boardman, Jordan J. Clark, Parul Sharma, Krishanthi Subramaniam, Greta K. Wood, Ceryce Collie, Richard Digby, Alexander Ren, Emma Norton, Maya Leibowitz, Soraya Ebrahimi, Andrew Fower, Hannah Fox, Esteban Tato, Mark A. Ellul, Geraint Sunderland, Marie Held, Claire Hetherington, ISARIC4C Investigators, COVID-CNS Consortium, …David K. Menon
Nature Communications volume 14, Article number: 8487 (2023) Cite this article
24k Accesses
1375 Altmetric
Metrics details
Abstract
To understand neurological complications of COVID-19 better both acutely and for recovery, we measured markers of brain injury, inflammatory mediators, and autoantibodies in 203 hospitalised participants; 111 with acute sera (1–11 days post-admission) and 92 convalescent sera (56 with COVID-19-associated neurological diagnoses). Here we show that compared to 60 uninfected controls, tTau, GFAP, NfL, and UCH-L1 are increased with COVID-19 infection at acute timepoints and NfL and GFAP are significantly higher in participants with neurological complications. Inflammatory mediators (IL-6, IL-12p40, HGF, M-CSF, CCL2, and IL-1RA) are associated with both altered consciousness and markers of brain injury. Autoantibodies are more common in COVID-19 than controls and some (including against MYL7, UCH-L1, and GRIN3B) are more frequent with altered consciousness. Additionally, convalescent participants with neurological complications show elevated GFAP and NfL, unrelated to attenuated systemic inflammatory mediators and to autoantibody responses. Overall, neurological complications of COVID-19 are associated with evidence of neuroglial injury in both acute and late disease and these correlate with dysregulated innate and adaptive immune responses acutely.
Similar content being viewed by others
Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study
Article Open access 09 November 2022
Longitudinal proteomic profiling reveals increased early inflammation and sustained apoptosis proteins in severe COVID-19
Article Open access 25 November 2020
Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19
Article Open access 12 October 2021
Introduction
At the beginning of the COVID-19 pandemic, neurological complications occurred in a significant proportion of hospitalised patients1 and even in those with mild COVID-19 infection2. While these neurological ‘complications’ were often mild (headache and myalgia), it became clear that more significant neurological sequelae were observed, including encephalitis/encephalopathies, Guillain Barre Syndrome, seizure, and stroke3,4,5,6.
Although in vitro studies show that SARS-CoV-2 can infect neurons and astrocytes7,8, autopsy studies indicate that direct viral invasion is unlikely to be a cause of neurological dysfunction in vivo9. Post-mortem studies failed to detect viral infection of the brain by immunohistochemistry in the majority of cases, and viral qPCR levels were often low and may simply have reflected viraemia10,11,12. In addition, virus and/or anti-viral antibodies were rarely found in cerebrospinal fluid (CSF)13. Thus, it seems more likely that the virus affects the brain indirectly. This could be through peripherally generated inflammatory mediators, immune cells, autoantibodies and/or blood brain barrier changes associated with endothelial damage14,15. Immune infiltrates have been found in autopsy studies, including neutrophils and T cells, although agonal effects could not be excluded16. On the other hand, elevated IL-6 levels in sera and CSF have been associated with neurological complications, including meningitis, thrombosis, stroke, cognitive and memory deficits, regardless of respiratory disease severity17,18,19,20. One study found that the brain injury markers NfL and GFAP, and inflammatory cytokines were elevated in COVID-19 and scaled with severity21,22,23,24,25; another study showed that baseline CSF NfL levels correlated with neurological outcomes at follow-up26 but overall, the relationships between these immune mediators and markers of brain injury and neuropathology remains to be fully explored. Finally, specific neuronal autoantibodies have been reported in some neurological patients raising the possibility of para- or post-infectious autoimmunity14,27.
To assess the relationship between host immune response and markers of brain injury with neurological injury, we studied two large, multisite cohorts which, in combination, provided acute, early and late convalescent sera from COVID-19-positive (COVID+ve) participants. We measured brain injury markers, a range of cytokines and associated inflammatory mediators, and autoantibodies in these samples, and related them to reduced levels of consciousness (defined as a Glasgow Coma Scale Score [GCS] GCS ≤ 14) in the acute phase, or the history of a neurological complication of COVID-19 in convalescent participants. We tested the hypothesis that immune mediators would correlate with brain injury markers and reveal a signature of neurological complications associated with COVID-19.
Results
COVID-19 results in acute elevation of serum markers of brain injury, more so in participants with abnormal Glasgow coma scale (GCS) score
We used sera from the International Severe Acute Respiratory and emerging Infection Consortium Clinical Characterisation Protocol United Kingdom (ISARIC CCP-UK) study, obtained 1–11 days post admission, that included 111 participants with COVID-19 of varying severity and 60 uninfected healthy controls (labelled Control). Participants were stratified by normal (n = 76) or abnormal (n = 35) Glasgow Coma Scale scores (labelled GCS = 15 or GCS ≤ 14, respectively) to provide a proxy for neurological dysfunction (Fig. 1a). GFAP (glial fibrillary acidic protein, marker of astrocyte injury), UCH-L1 (a marker of neuronal cell body injury), and NfL (neurofilament light) and Tau (both markers of axonal and dendritic injury) were measured. Overall, serum levels of NfL, GFAP, and total-Tau (tTau) were significantly higher in COVID-19 participants compared to the uninfected healthy controls but, as shown in Fig. 1b–e, those participants with abnormal GCS scores had higher levels of NfL and UCH-L1 than those with normal GCS scores. Thus, all four markers of brain injury were raised in COVID-19 participants (both GCS = 15 and GCS ≤ 14) but, in addition, axonal and neuronal body injury biomarkers discriminated between participants with and without reduced GCS.
Fig. 1: Brain injury markers are elevated acutely in COVID-19 participants with an abnormal Glasgow coma scale score (GCS) and in participants who experienced a neurological complication associated with COVID-19.
figure 1
a The acute ISARIC cohort included Day 1–11 hospital admission timepoints. b–e Acute serum brain injury markers were assessed by Simoa: b NfL, c UCH-L1, d GFAP, and e tTau. All four were elevated in COVID-19 cases with normal Glasgow coma scale scores (GCS) relative to controls overall. Dotted lines show lower limit of quantification (LLOQ). f–j The Simoa analyses were performed for the sera from the COVID-CNS COVID and neuro-COVID groups at early and late convalescent timepoints (g, j) showing persistence of NfL, GFAP, and tTau in COVID participants, with NfL higher in neuro-COVID than COVID participants. k Within the combined early and late convalescent COVID-19 neurological cases, the highest levels of NfL were observed in participants who had suffered a cerebrovascular event at the time of SARS-CoV-2 infection. l tTau levels were raised in the cerebrovascular, CNS inflammatory and seizure conditions. m, n Serum NfL remained elevated in both the early (<6 weeks from positive SARS-CoV-2 test) and late convalescent phases (>6 weeks) in neuro-COVID compared to COVID non-neurological cases. o, p GFAP was elevated in neurological cases in the early and late convalescent phase. Box and whisker plots show all data points with median as centre line with 25th and 75th percentiles. Sample sizes shown in (a) and (f). Group comparisons are by Kruskal–Wallis test with Dunn’s post-hoc multiple comparison test, no statistical comparison made for panel (h) as medians were at LLOQ.
Full size image
Markers of brain injury remain elevated in the early and late convalescent phases in participants who have had a CNS complication of COVID-19
To ask whether these findings persisted in participants recovering from COVID-19-related neurological complications, ninety-two COVID-19 participants were recruited to the COVID-Clinical Neuroscience Study (COVID-CNS), 56 who had had a new neurological diagnosis that developed as an acute complication of COVID-19 (group labelled “neuro-COVID”), and 36 with no such neurological complication (group labelled “COVID”, Fig. 1f, Table 1, Supplementary Tables 1 and 2). When compared to the same healthy controls (n = 60), across all timepoints, both COVID-19 subgroups (COVID and neuro-COVID) showed increased levels of NfL, GFAP, and tTau (but not UCH-L1 (Fig. 1g–j, Supplementary Table 1)). Furthermore, participants recovering from neuro-COVID had significantly higher levels of NfL, and a trend towards higher levels of tTau, than the COVID participants (Fig. 1g, j). Highest NfL serum levels were present in participants with cerebrovascular conditions, whereas tTau was elevated in participants with cerebrovascular, CNS inflammation and peripheral nerve complications (Fig. 1k, l). NfL remained significantly elevated in a multiple regression model adjusted for age (Supplementary Fig. 1a, b). We then separately compared the two cohorts at early and late convalescent follow-up periods (less than and over six weeks after admission respectively). NfL and GFAP levels remained elevated in all COVID-19 participants in the convalescent period, but only remained elevated beyond 6 weeks in participants who had suffered an acute neurological complication (neuro-COVID, Fig. 1m–p; Supplementary Fig. 1c). The presence of elevated brain injury markers in the acute phase of COVID-19 confirms previous findings14, but the elevated levels of NfL and GFAP in those who are convalescent from acute neurological complications suggest ongoing neuroglial injury.
Table 1 Clinical characteristics of healthy controls and COVID-CNS participants
Full size table
Clinical and brain injury markers evidence of neurological insult levels are associated with levels of innate inflammatory mediators in the acute phase of COVID-19
To explore whether the acute and persistent elevation of markers of brain injury observed in participants with COVID-19 was associated with an acute inflammatory response, we measured a panel of 48 inflammatory mediators in serum at the same timepoints. In the ISARIC samples, six mediators were significantly higher in participants with an abnormal GCS than in those with a normal GCS (interleukin [IL]-6, hepatocyte growth factor [HGF], IL-12p40, IL-1RA, CCL2 and macrophage colony stimulating factor [M-CSF]), indicating increased innate inflammation (Fig. 2a, Supplementary Fig. 2a). Pearson’s correlation tests identified correlations between these significant immune mediators in an interrelated pro-inflammatory network (Fig. 2b, c), and unsupervised Euclidean hierarchical cluster analysis revealed clusters of pro-inflammatory mediators elevated together (Fig. 2d). The first cluster incorporated the IL-1 family (including IL-1RA), interferons and M-CSF, and the second cluster included IL-6, CCL2, CXCL9, HGF, and IL-12p40 (boxes in Fig. 2d). Brain injury biomarkers correlated with elevations in these inflammatory mediators: GFAP and UCL-H1 correlated with a number of mediators in the first cluster, whereas tTau and NfL correlated strongly with HGF and IL-12p40 in the second cluster (Supplementary Table 3).
Fig. 2: Immune mediators are elevated acutely and correlate with different brain injury markers at different timepoints.
figure 2
Serum mediators from the ISARIC and COVID-CNS cohorts were assessed by Luminex. a A volcano plot was generated to identify mediators which were elevated in participants with an abnormal GCS (GCS ≤ 14) compared to normal GCS (GCS = 15) and b, c a network analysis identified the highest correlations between the mediators (***significantly different from ISARIC GCS = 15 by Steiger test p < 0.001). d Unbiased Euclidean hierarchical cluster and correlation analyses identified two clusters of up-regulation of several pro-inflammatory mediators in concert. The first group included interleukin (IL)-6, IL-12p40, CCL2, CXCL9 and hepatocyte growth factor (HGF) and the second group included the IL-1 family, interferons, and macrophage colony stimulating factor (M-CSF); to the right is shown the correlations between each cytokine with the four brain injury biomarkers (significance indicated by asterisks). e Network analysis and heatmaps of correlations between mediators did not demonstrate the tight interconnectedness that had been identified in acute samples and there were differences between neuro-COVID (e) and ISARIC GCS = 15 and GCS ≤ 14 by Steiger test (***p < 0.001). f At this later stage several mediators correlated with tTau. Volcano plot used multiple two-tailed Mann–Whitney U tests with a false discovery rate set to 5%. Correlations are Pearson’s coefficients (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
Full size image
A more stringent analysis of median-centred cytokine data (which corrected for between participant skewing of mediator levels) confirmed that HGF and IL-12p40 were higher in the abnormal GCS COVID-19 participants, and correlated with cognate NfL levels (Supplementary Table 4). Taken together these data suggest that activation of the innate immune system was related to both clinical and blood marker evidence of CNS insult.
Inflammatory mediators are not elevated across the participant cohort at late timepoints after COVID-19; but late tTau elevations correlate with levels of several inflammatory mediators
In contrast to the acute data, the levels of cytokines and associated mediators were lower when measured during the convalescent periods even in those who had suffered neurological complications of COVID-19 (group labelled “neuro-COVID”. Supplementary Fig. 2b). The correlations between cytokines and associated mediators no longer displayed the same tight clusters (Fig. 2e, f). GFAP remained elevated during the convalescent phase of neurological complications (Fig. 1p) but did not show correlations with the inflammatory mediators. Similarly NfL was higher overall in those with neurological complications (Fig. 1n) but there were no significant correlations with inflammatory mediators (Fig. 2f). However, tTau remained elevated overall in those with neurological complications ((1.7 (1.3, 2.2) pg/mL versus 1.3 (1.1, 1.9) pg/mL)) and levels correlated with eight immune mediators including CCL2, IL-1RA, IL-2Rα and M-CSF along with CCL7, stem cell factor (SCF), IL-16 and IL-18 (Fig. 2f, Supplementary Table 5, Supplementary Fig. 2c). This last association was specific to the late phase of the illness and was not found in acute COVID-19.
Cytokine networks are significantly altered in participants with neurological complications of COVID-19: both acute encephalopathy, and those recovering from a neurological complication
We used graph theoretical approaches to compare these cytokine networks between participants with: acute COVID-19 and normal GCS; acute COVID-19 with altered consciousness (GCS ≤ 14), and convalescent participants recovering from a neurological complication of COVID-19 (neuro-COVID). Participants with both neurological consequences of COVID-19 (GCS ≤ 14) and Neuro-COVID both showed cytokine networks that were different from COVID-19 participants with no neurological problems (Fig. 2b, c, e; p < 0.001, Steiger test), suggesting a specific dysregulated innate immune response that is associated with neurological complications of COVID-19. Further pathway analyses using the KEGG enrichment scores on the significantly different cytokines, revealed many commonalities with other inflammatory syndromes (Supplementary Fig. 3a, b). Interestingly, cytokine profiles of the neurological complications groups from both the ISARIC and COVID-CNS cohort led to JAK-STAT signalling being a significant involved pathway which would be amenable to immunomodulation, for example, by tofacitinib, which has been shown to reduce mortality in COVID-1928.
COVID-19 is associated with an acute adaptive immune response overall, which includes antibodies to viral antigen and CNS autoantigens in those with abnormal GCS scores
Given past reports of autoantibody responses following COVID-1914,27, we sought evidence of similar dysregulated adaptive immune responses in our participant cohorts. We used a bespoke protein microarray of 153 viral and tissue proteins to measure IgM (Fig. 3a–d) and IgG (Fig. 4a–d) reactivity in the acute phase ISARIC sera. The median fluorescence intensities for each putative antigen were normalized for each participant and the Z-scores were compared to healthy control data, to determine positive reactivity to the different antigens (with a threshold for detection set at three standard deviations above controls for each antigen; see Supplementary Table 6, Supplementary Fig. 4a). IgM and IgG responses in COVID-19 participants showed greater reactivity overall (both GCS = 15 and GCS ≤ 14), compared to the controls, with no difference in normalised fluorescence Z scores or the number of participants with IgG ‘hits’ (a Z-score >3) between those with normal or abnormal GCS score (Fig. 3a, b, Fig. 4a, b). However, several IgM and IgG autoantibodies, including those against the CNS antigens UCH-L1, GRIN3B and DRD2, along with the cardiac antigen, myosin light chain (MYL)-7, were present in a greater proportion of participants with an abnormal GCS score, as were antibodies to spike protein (Figs. 3c, 4c). None of the antibodies correlated significantly with levels of brain injury markers (Supplementary Figs. 4b, c, 5b, c), but they did show correlations with each other (Figs. 3d, 4d, h), suggesting a non-specific antibody response in some individuals during the acute phase.
Fig. 3: There is an IgM antibody response in participants with COVID-19 directed at SARS-CoV-2 spike protein and against several self-antigens.
figure 3
a Acute samples were tested for IgM antibodies by protein microarray with normalized fluorescence Z-scores shown. b COVID-19 participants showed considerably more binding ‘hits’ than healthy controls (fluorescence with a Z-score of 3 or above compared to controls), although overall there was no difference in the acute samples between participants with normal (GCS = 15) or abnormal GCS (GCS ≤ 14)). Nevertheless, c COVID-19 participants with abnormal GCS (GCS ≤ 14) more frequently had raised IgM antibodies than COVID-19 participants with a normal GCS (GCS = 15), including those directed at SARS-CoV-2 spike protein (Fisher’s exact tests *p < 0.05). d A chord diagram shows the associations between antibodies, including those against Spike. e IgM antibodies were also analysed in the convalescent participants. f A largr proportion of COVID and Neuro-COVID participants had positive antibody ‘hits’ for IgM (defined by Z-score 3 and above compared to controls). g Of those antibodies against self-antigens identified, they were only two with different frequencies between the groups (Fisher’s exact tests *p < 0.05). At this timepoint there was no significant difference in the proportion of individuals with IgM against SARS-CoV-2 spike or nucleocapsid epitopes. Violin plots show all data points with median at centre line and 25th and 75th quartile lines. Group comparisons are by Kruskal–Wallis test with post-hoc Dunn’s multiple comparison test, pairwise comparisons by two-tailed Mann–Whitney U test, and correlations are Pearson’s coefficients.
Full size image
Fig. 4: There is an IgG antibody response in participants with COVID-19 directed at SARS-CoV-2 nucleocapsid and spike proteins and against several self-antigens.
figure 4
a Acute samples were tested for IgG antibodies by protein microarray with normalized fluorescence Z-scores shown. b COVID-19 participants showed considerably more binding ‘hits’ than healthy controls (fluorescence with a Z-score of 3 or above compared to controls) but, overall, there was no difference in the acute samples between participants with normal (GCS = 15) or abnormal GCS (GCS ≤ 14). c COVID-19 participants with abnormal GCS more frequently had several raised IgG antibodies than COVID-19 participants with a normal GCS, including those directed at SARS-CoV-2 spike protein and several CNS proteins ((DRD2, GRIN3B, and UCH-L1) Fisher’s exact tests * p < 0.05)). d A chord diagram shows the association of antibodies with differences in frequency, including those against Spike. e IgG antibodies in early and late convalescent sera were also analysed. f A larger proportion of Neuro-COVID participants had positive antibody ‘hits’ for IgG (defined by Z-score 3 and above compared to controls). g Of those antibodies against self-antigens identified, only five showed a difference in frequency between groups (Fisher’s exact tests *p < 0.05). At this timepoint there was no significant difference in the proportion of individuals with IgG against SARS-CoV-2 spike or nucleocapsid epitopes. h A chord diagram shows the association of antibodies with differences in frequency plus anti-Spike antibody. i Representative images of rat brains incubated with participants’ sera and screened for IHC binding of anti-human IgG to detect CNS reactivity. Scale bars = 1 mm. j Percentage of participant serum IgG reactivity to rat brainstems, detected by Fisher’s exact test with Benjamini and Hochberg correction. Violin plots show all data points with median at centre line and 25th and 75th quartile lines. Group comparisons are by Kruskal–Wallis test with post-hoc Dunn’s multiple comparison test, pairwise comparisons by two-tailed Mann–Whitney U test, and correlations are Pearson’s coefficients.
Full size image
Normalized fluorescence Z scores of serum IgM and IgG autoantibodies in the early and late convalescent samples were similar to those in the acute samples (Figs. 3e, 4e), and the IgM and IgG ‘hits’ were more frequent than in controls (highest in the neuro-COVID group, Figs. 3f, 4f, Supplementary Fig. 5a). However, specific autoantibody responses to MYL7, gonadotrophin releasing hormone receptor (GNRHR) and several HLA antigens were common in the neuro-COVID participants (Figs. 3g, 4g, Supplementary Fig. 5a). When the IgM and IgG hits were stratified by condition, cerebrovascular and inflammatory conditions showed the highest number (Supplementary Fig. 5d, e). As in the acute phase, autoantibody responses did not show significant associations with brain injury markers, but did tend to correlate with each other (Fig. 4h, Supplementary Fig. 5b, c).
Finally, to explore binding to native neuronal antigens, sera from acute COVID-19 participants with CNS antigen reactivity were incubated with sections of rat brain, neurons and antigen-expressing cells. Binding to rat brain sections identified 42/185 (23%) of participants with strongly positive immunohistochemical staining (e.g. Fig. 4i) and overall, sera from the COVID+ve ISARIC participants showed more frequent binding to brainstem regions than control sera, but this did not relate to the GCS or neurological disease of the participants (Fig. 4j, Supplementary Fig. 6). In addition, from 34 selected samples tested via cell-based assays to examine for the presence of specific autoantibodies (LGI1, CASPR2, NMDAR, GABAB receptor), only one bound to the extracellular domain of the GABAB receptor (from the ISARIC cohort, Supplementary Fig. 7a, b), as expected of a pathogenic autoantibody.
Discussion
We used several approaches to study neurological complications of COVID-19 infection. These included assessment of immune mediators and markers of brain injury in participants with and without neurological complications, both in the acute and convalescent phases after COVID-19 infection. We demonstrated increased levels of brain injury markers following COVID-19, which showed specific patterns with disease phase (acute or convalescent), and varied with the presence or absence of neurological injury or dysfunction. In the acute phase, all four brain injury markers (GFAP, NfL, tTau and UCH-L1) were elevated in participants when compared to controls, and specific markers of dendritic and axonal injury (tTau and NfL) were significantly higher in participants who showed a reduced level of consciousness (GCS ≤ 14). In the early convalescent phase (<6 weeks post-infection), GFAP, NfL, and tTau were elevated in participants recovering from COVID-19, with no differences between those who had or had not sustained a neurological complication of disease. However, at late timepoints (>6 weeks) elevations of NfL and GFAP were only seen in participants who had sustained a neurological complication of COVID-19 in the acute phase of their illness. These data suggest that clinical neurological dysfunction in COVID-19 is reflected by increases in markers of neuroglial injury, both in the acute phase and at follow-up, which are related to a dysregulated immune response, more robustly in the acute phase of illness.
In the acute phase, when compared to controls, we also observed increases in a range of inflammatory mediators (IL-6, HGF, IL-12p40, IL-1RA, CCL2, and M-CSF) in the overall cohort of COVID-19 participants, with HGF and IL-12p40 showing robust differentiation between participants with and without alterations in consciousness. By contrast, participants at the late phase after COVID-19 showed no group level elevation of inflammatory mediators. However, late elevations in tTau correlated with levels of CCL2, CCL7, IL-1RA, IL-2Rα, M-CSF, SCF, IL-16, and IL-18, suggesting that these markers of the late innate host response were associated with persisting markers of dendritic/axonal injury markers. A network analysis showed that the repertoire of cytokine responses was different in participants both with acute reductions in GCS, or those recovering from a neurological complication of COVID-19 when compared to the GCS = 15 group.
Participants with acute COVID-19 also developed IgG autoantibody responses to a larger number of both neural and non-neural antigens, than seen in controls. These increased IgG responses persisted into the late phase but to different antigens. While the diversity of autoantibody response did not differ between participants with and without neurological dysfunction, autoantibody responses to specific antigens, including the neural antigens UCH-L1, GRIN3B, and DRD2, were more common in participants with abnormal GCS at presentation. In the late phase, participants who had or had not experienced a neurological complication of COVID-19 were distinguished by the presence of autoantibodies to HLA antigens rather than neural antigens.
These data from clinical disease provide important insights regarding the pathophysiology and pathogenesis of neurological injury, dysfunction, and disease in COVID-19. The clinical characteristics of our participant cohorts, and the elevation in brain injury markers, provide evidence of both acute and ongoing neurological injury29. Furthermore, the literature data on the rarity of direct CNS infection by the virus, suggest that the innate and adaptive host responses that we document should be explored as pathogenic mechanisms. The incidence of neurological cases has decreased since the first wave of the pandemic, possibly due to the use of immunosuppressants, such as dexamethasone, although this may also reflect vaccines attenuating disease and changes in the prevalence of different strains of SARS-CoV-230.
The inflammatory mediators that we found to be elevated in the acute phase are broadly concordant with many other publications that have examined innate immune responses in COVID-1921,22 but there are limited data addressing associations between such responses and the development of neurological complications. It is possible that some of the risk of developing such complications is simply related to the severity of systemic infection and the host response, and it would be surprising if these were not strong contributors. However, our data suggest that acute neurological dysfunction in COVID-19 is also associated with a different repertoire of cytokine responses, with HGF and IL-12p40 showing the statistically most robust discrimination between participants with and without an abnormal GCS. HGF has important roles in brain development and synaptic biology31 and its elevation may represent a protective/reparative response in participants with neurological injury. IL-12p40 has a core role in orchestrating Th1 responses, and has been reported to be central in the development of central and peripheral neuroinflammation, with p40 monomer subunits perhaps acting as inhibitors of the process32,33,34. Interestingly, the cytokine network that was activated in the late convalescent phase was different, potentially indicating differential drivers of neurological injury throughout the disease course. Though group level comparisons with controls showed some commonalities in inflammatory mediator increase, most notably in IL-1RA, CCL2, and M-CSF, there were many differences. The late tTau elevation that we demonstrated was significantly associated with elevations in these three mediators, but also CCL7, IL-2Rα, SCF, IL-16, and IL-18. These are all important pro-inflammatory mediators, and their association with tTau levels may reflect the persistence of a systemic inflammatory response that can enhance neuroinflammation32,34,35.
We found a general increase in antibody production following COVID-19 infection and only a few autoantibody frequencies were different when compared by GCS or COVID versus neuro-COVID cases. Of note, absolute levels of autoantibodies were low in comparison to anti-viral antibodies that developed over the course of the acute illness, with the exception of SFTPA1. Antibodies to SFTPA1, a lung surfactant protein, have been found to correlate with COVID-19 severity14, but these antibodies were present in only a few acute cases. HLA antibodies, on the other hand, were more frequent in Neuro-COVID than COVID participants and this requires further investigation. The autoantibodies detected in COVID-19, as in other infections, could be through molecular mimicry or bystander effects36,37,38,39, but the lack of association of autoantibody levels with markers of brain injury is evidence against a causal role for these adaptive immune responses. Further analysis by screening the antibodies against brain antigens ex vivo revealed sporadic reactivity in both cases and controls with only the brainstem showing increased reactivity in acute COVID+ve participants; the frequencies were lower in COVID and neuro-COVID cases with no difference between them.
Our studies have several limitations including: limited clinical information on the acute participants and lack of longitudinal blood samples; in addition, the low GCS could indicate sedation for intubation, rather than CNS disease, in the acute cohort. Although we did not have COVID-19 severity scores, we did know whether participants had required oxygen or not; when data were analysed within the cohorts comparing participants who had or had not required oxygen, 5 out of 6 cytokines remained significantly elevated in the abnormal GCS group. In the COVID-CNS study where we did have in-depth clinical information, we were limited by not having acute blood samples. Nevertheless, several cytokines showed significant positive correlations with the brain injury marker tTau, and interestingly, three of them were cytokines that were significantly associated with abnormal GCS in the acute cohort (IL-1RA, CCL2, and M-CSF) highlighting a network of co-upregulated immune mediators associated with neurological complications. The commonalities in innate immune response in participants who suffered neurological dysfunction/complications, both in the acute phase and at convalescence, is underlined by the results of network analysis. Pro-inflammatory cytokines are expected to be increased in the anti-viral response, but we found that they not only correlate with COVID-19 severity, but with GCS, as well. Strengths of our study include the large cohort of participants studied with well-characterized neurological syndromes and a known range of timings since COVID-19 infection. We studied aspects of the innate and adaptive immune response as well as brain injury markers in order to discover useful markers of neurological complications over time.
Several hypotheses for how SARS-CoV-2 causes neuropathology have been tested. A prospective study of hospitalised patients showing IL-6 and D-dimer as risk factors for neurological complications implicates the innate immune response and coagulation pathways19. The complement pathway and microthrombosis have been associated with brain endothelial damage from the infection, and this phenotype persists months after COVID-1940,41. Animal models have provided key insights into COVID-19 neuropathology that warrant discussion. There have been at least two reports of viral encephalitis and neuron degeneration and apoptosis observed in non-human primates42,43. It is important to note that in these studies the virus was present at low amounts in the brain and predominantly in the vasculature as visualized by co-localization with Von Willebrand Factor43. Similar to the clinical scenario, there was no correlation of neuropathology with respiratory disease severity43. A recent mouse study is particularly relevant to our work and involved assessment of a mouse model that lacked direct viral neural invasion by infecting mice that were intratracheally transfected with human ACE2. This study reported increased CXCL11 (eotaxin) in mouse serum and CSF that correlated with demyelination and was recapitulated by giving CXCL11 intraperitoneally44; this was linked to clinical studies that showed elevated CXCL11 in patients with brain fog44. A combined analysis of hamster and clinical studies showed that COVID-19 led to IL-1β and IL-6 expression within the hippocampus and medulla oblongata and decreased neurogenesis in the hippocampal dentate gyrus which may relate to learning and memory deficits45. This was also borne out during in vitro studies that showed that serum from COVID patients with delirium lead to decreased proliferation and increased apoptosis of a human hippocampal progenitor cell line mediated by elevated IL-646.
In conclusion, we show evidence of quantifiable neuroglial injury markers in blood from COVID-19 infection, which is more prominent in patients with neurological dysfunction in the acute phase of the illness, and persists in the convalescent phase in patients who suffered defined acute neurological complications. These brain injury markers are associated with dysregulated systemic innate and adaptive immune responses in the acute phase of the disease, and suggest that these may represent targets for therapy.
Methods
Human participant studies/healthy controls and ethics information
The ISARIC WHO Clinical Characterization Protocol for Severe Emerging Infections in the UK (CCP-UK) was a prospective cohort study of hospitalised patients with COVID-19, which recruited across England, Wales, and Scotland (National Institute for Health Research Clinical Research Network Central Portfolio Management System ID: 14152). Participants were recruited prospectively during their hospitalisation with COVID-19 between February 2020 and May 2021. The protocol, revision history, case report form, patient information leaflets, consent forms and details of the Independent Data and Material Access Committee are available online47. Ethical approval for CCP-UK was given by the South Central - Oxford C Research Ethics Committee in England (Ref 13/SC/0149) and the Scotland A Research Ethics Committee (Ref 20/SS/0028). We examined 111 participants with anonymized clinical data including Glasgow coma scale score and consented serum sample. ISARIC samples were collected during the acute phase (1–11 days from hospital admission). Healthy control participants between the ages of 20–79 years old were recruited through the Cambridge Biomedical Research Centre (prior to the COVID-19 pandemic) and were non-hospitalised, without SARS-CoV-2 infection, and had no neurological diagnoses. All participants provided written consent. Sex was not considered in the study design and the sex of participants was self-reported.
Participants were recruited into the COVID-Clinical Neuroscience Study (COVID-CNS) between October 2020 and October 2022 and either the participant or their next of kin consented in accordance with the ethically-approved NIHR Bioresource (East of England—Cambridge Central Research Ethics Committee (Ref 17/EE/0025; 22/EE/0230). The purpose of the study was to investigate patients who had been hospitalised with COVID-19 with or without neurological complications. These were defined by the following criteria: neurological disease onset within 6 weeks of acute SARS-CoV-2 infection and no evidence of other commonly associated causes, and diagnostic criteria previously described48. Participants were recruited both as in-patients and retrospectively after discharge. The diagnosis was reviewed and finalized by a multi-disciplinary Clinical Case Evaluation panel. In this study, there were COVID patients without neurological complications (COVID-controls) and COVID patients with neurological complications (Neuro-COVID cases) and these cases were stratified by diagnostic definitions of each type of neurological complication, very few had overlapping syndromes in this relatively small cohort and the Evaluation Panel were able to provide a primary diagnosis for all”4. Co-morbidities and known treatments are shown in Supplementary Table 7. Serum samples were collected at either the early (<6 weeks from COVID-19 positive test) or late convalescent (>6 weeks) phases. The samples were aliquoted, labelled with anonymised identifiers, and frozen immediately at −70 °C.
Human brain injury markers measurements
Brain injury markers were measured in thawed sera using a Quanterix Simoa kit run on an automated HD-X Analyser according to the manufacturer’s protocol (Quanterix, Billerica, MA, USA, Neurology 4-Plex B Advantage Kit, cat#103345). We assessed neurofilament light chain (NfL), Ubiquitin C-Terminal Hydrolase L1 (UCH-L1), total-Tau (tTau), and glial fibrillary acidic protein (GFAP) in sera diluted 1:4 and used the manufacturer’s calibrators to calculate concentrations.
Human serum cytokine measurements
Analytes in thawed sera were quantified using the BioRad human cytokine screening 48-plex kit (Cat# 12007283) following manufacturer’s instructions on a Bioplex 200 using Manager software 6.2. This involved incubation of 1:4 diluted sera with antibody-coated magnetic beads, automated magnetic plate washing, incubating the beads with secondary detection antibodies, and adding streptavidin-PE. Standard curves of known protein concentrations were used to quantify analytes. Samples that were under the limit of detection were valued at the lowest detectable value adjusted for 1:4 dilution factor.
Median-centred normalization of human serum cytokine measurements
To minimise any potential impact of any possible variation in sample storage and transport, concentrations were median-centred and normalised for each participant, using established methodology49,50,51. The pg/mL of cytokines were log-transformed and the median per participant across all cytokines was calculated. The log-transformed median was subtracted from each log-transformed value to generate a normalized set.
Protein microarray autoantibody profiling
Autoantibodies were measured from thawed sera as previously described in Needham et al.14. Briefly, a protein array of antigens (based on the HuProt™ (version 4.0) platform) was used to measure bound IgM and IgG from sera, using secondary antibodies with different fluorescent labels detected by a Tecan LS400 scanner and GenePix Pro v4 software. As developed in previous studies14,52, antibody positivity was determined by measuring the median fluorescence intensity (MFI) of the four quadruplicate spots of each antigen. The MFI was then normalized to the MFI of all antigens for that patient’s sample by dividing each value by the median MFI. Z-scores were obtained from these normalized values based on the distribution derived for each antigen from the healthy control cohort. A positive autoantibody ‘hit’ was defined as an antigen where Z ≥ 3.
Detection of antibodies by immunohistochemistry
Immunohistochemistry was performed on sagittal sections of female Wistar rat brains. Brains were removed, fixed in 4% paraformaldehyde (PFA) at 4 °C for 1 h, cryoprotected in 40% sucrose for 48 h, embedded in freezing medium and snap-frozen in isopentane chilled on dry ice. 10-µm-thick sections were cut and mounted on slides in a cryostat. A standard avidin-biotin peroxidase method was used, as reported previously53,54, where thawed sera were diluted 1:200 in 5% normal goat serum and incubated at 4 °C overnight, and secondary biotinylated goat anti-human IgG Fc was diluted (1:500) and incubated at room temperature for 1 h. Finally, slides were counter-stained using cresyl violet.
Detection of autoantibodies with cell-based assays
HEK293T cells were seeded on 96 well plates in DMEM + 10% FCS at 37 °C and 5% CO2, transiently transfected with polyethylenimine with the relevant antigen-encoding plasmids GABAB-R1 and GABAB-R2 of the GABAB receptor, membrane tethered LGI1, CASPR2 and the NR1 subunit of the NMDA receptor, as described previously55,56,57. Thawed serum samples were incubated at 1:100 dilution for CASPR2 and GABAB receptor assays, and at 1:20 for LGI1 and NMDAR. After washing, cells were fixed with 4% PFA, washed again and incubated with unconjugated goat anti-human IgG Fc antibody, and donkey anti-goat IgG heavy and light chain Alexa Fluor 568 antibody. Cells were co-stained with DAPI.
Statistical analyses
Prism software (version 9.4.1, GraphPad Software Inc.) was used for graph generation and statistical analysis. The Shapiro-Wilk normality test used to check the normality of the distribution. Individual data points, median lines, and first and third quartiles are shown on box and whisker plots and violin plots with minimum and maximum points as error bars. Heatmaps, volcano plots and Chord diagrams were made using R studio (version 4.1.1 RStudio, PBC). The 2D cytokine network analyses were created using the qgraph package in R software and matrices differences were assessed by Steiger test58. Univariate analyses were conducted to test for differences between two groups. Differences between two normally distributed groups were tested using the paired or unpaired Student’s t test as appropriate. The difference between two non-normally distributed groups was tested using Mann–Whitney U test. Volcano plots used multiple Mann–Whitney U tests with a false discovery rate set to 5%, and heatmaps show Pearson’s correlations adjusted for a false discovery rate of 5%. Group comparisons were by Kruskal–Wallis test. Frequency differences of antibodies were measured by Fisher’s exact tests. Proteins which were statistically significantly different in the COVID-positive controls (GCS = 15 or COVID groups, respectively) versus the GCS less than or equal to 14 or neurological cases by Mann-Whitney test (p ≤ 0.05) were analysed with the KEGG (Kyoto Encyclopedia of Genes and Genomes) database. Pathway classifications from the KEGG map search results were ranked by highest number of mapped candidates and exported in the KGML format using R package clusterProfiler. p ≤ 0.05 was considered statistically significant.
Reporting summary
Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.
Data availability
The individual-level data from these studies is not publicly available to main confidentiality. Data generated by the ISARIC4C consortium is available for collaborative analysis projects through an independent data and materials access committee at isaric4c.net/sample_access. Data and samples from the COVID-Clinical Neuroscience Study are available through collaborative research by application through the NIHR bioresource at
https://bioresource.nihr.ac.uk/using-our-bioresource/apply-for-bioresource-data-access/. Brain injury marker and immune mediator data are present in the paper and in the source data file. Source data are provided with this paper.
References
Drake, T. M. et al. Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet 398, 223–237 (2021).
Article
CAS
PubMed
PubMed Central
Google Scholar
Xu, E., Xie, Y. & Al-Aly, Z. Long-term neurologic outcomes of COVID-19. Nat. Med. 1–10
https://doi.org/10.1038/s41591-022-02001-z (2022).
Varatharaj, A. et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry 7, 875–882 (2020).
Article
PubMed
PubMed Central
Google Scholar
Ross Russell, A. L. et al. Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance study. Brain Commun. 3, fcab168 (2021).
Article
PubMed
PubMed Central
Google Scholar
Paterson, R. W. et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain 143, 3104–3120 (2020).
Article
PubMed
PubMed Central
Google Scholar
Mao, L. et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 77, 683–690 (2020).
Article
PubMed
Google Scholar
Song, E. et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J. Exp. Med. 218, e20202135 (2021).
Article
CAS
PubMed
PubMed Central
Google Scholar
Crunfli, F. et al. Morphological, cellular, and molecular basis of brain infection in COVID-19 patients. Proc. Natl Acad. Sci. USA 119, e2200960119 (2022).
Normandin, E. et al. Neuropathological features of SARS-CoV-2 delta and omicron variants. J. Neuropathol. Exp. Neurol. 82, 283–295 (2023).
Article
CAS
PubMed
Google Scholar
Meinhardt, J. et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci. 24, 168–175 (2021).
Article
CAS
PubMed
Google Scholar
Thakur, K. T. et al. COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. Brain 144, 2696–2708 (2021).
Article
PubMed
PubMed Central
Google Scholar
Khan, M. et al. Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. Cell 184, 5932–5949.e15 (2021).
Article
CAS
PubMed
PubMed Central
Google Scholar
Domingues, R. B., Leite, F. B. V. de M. & Senne, C. Cerebrospinal fluid analysis in patients with COVID-19-associated central nervous system manifestations: a systematic review. Arq. Neuropsiquiatr.
https://doi.org/10.1590/0004-282X-ANP-2021-0117 (2022).
Needham, E. J. et al. Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses. Brain awac321,
https://doi.org/10.1093/brain/awac321 (2022).
Dunai, C., Collie, C. & Michael, B. D. Immune-mediated mechanisms of COVID-19 neuropathology. Front. Neurol. 13, 782 (2022).
Maiese, A. et al. SARS-CoV-2 and the brain: a review of the current knowledge on neuropathology in COVID-19. Brain Pathol. 31, e13013 (2021).
Article
CAS
PubMed
PubMed Central
Google Scholar
Reinhold, D. et al. The brain reacting to COVID-19: analysis of the cerebrospinal fluid proteome, RNA and inflammation. J. Neuroinflammation 20, 30 (2023).
Article
CAS
PubMed
PubMed Central
Google Scholar
Fara, M. G. et al. Macrothrombosis and stroke in patients with mild COVID-19 infection. J. Thromb. Haemost. 18, 2031–2033 (2020).
Article
CAS
PubMed
PubMed Central
Google Scholar
Frontera, J. A. et al. A prospective study of neurologic disorders in hospitalized patients with COVID-19 in New York City. Neurology 96, e575–e586 (2021).
Article
CAS
PubMed
PubMed Central
Google Scholar
Hampshire, A. et al. Multivariate profile and acute-phase correlates of cognitive deficits in a COVID-19 hospitalised cohort. eClinicalMedicine 47, 101417 (2022).
Article
PubMed
PubMed Central
Google Scholar
Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463–469 (2020).
Article
CAS
PubMed
PubMed Central
Google Scholar
Thwaites, R. S. et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Sci. Immunol. 6, eabg9873 (2021).
Article
PubMed
PubMed Central
Google Scholar
Perreau, M. et al. The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients. Nat. Commun. 12, 4888 (2021).
Article
ADS
CAS
PubMed
PubMed Central
Google Scholar
Li, L. et al. Interleukin-8 as a biomarker for disease prognosis of coronavirus disease-2019 patients. Front. Immunol. 11, 602395 (2021).
Kanberg, N. et al. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. EBioMedicine 70, 103512 (2021).
Guasp, M. et al. CSF biomarkers in COVID-19 associated encephalopathy and encephalitis predict long-term outcome. Front. Immunol. 13, 1600 (2022).
Bertin, D. et al. Anticardiolipin IgG autoantibody level is an independent risk factor for COVID‐19 severity. Arthritis Rheumatol. Hoboken Nj 72, 1953–1955 (2020).
Article
CAS
Google Scholar
Guimarães, P. O. et al. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N. Engl. J. Med. 385, 406–415 (2021).
Article
PubMed
Google Scholar
Thelin, E. P. et al. Serial sampling of serum protein biomarkers for monitoring human traumatic brain injury dynamics: a systematic review. Front. Neurol. 8, 300 (2017).
Grundmann, A. et al. Impact of dexamethasone and remdesivir on neurological complications during COVID-19.
https://doi.org/10.2139/ssrn.4065552 (2022).
Desole, C. et al. HGF and MET: from brain development to neurological disorders. Front. Cell Dev. Biol. 9, 683609 (2021).
Bao, L. et al. The critical role of IL-12p40 in initiating, enhancing, and perpetuating pathogenic events in murine experimental autoimmune neuritis. Brain Pathol. 12, 420–429 (2002).
Article
CAS
PubMed
Google Scholar
Mondal, S. et al. IL-12 p40 monomer is different from other IL-12 family members to selectively inhibit IL-12Rβ1 internalization and suppress EAE. Proc. Natl Acad. Sci. USA 117, 21557–21567 (2020).
Article
ADS
PubMed
PubMed Central
Google Scholar
Kroenke, M. A., Carlson, T. J., Andjelkovic, A. V. & Segal, B. M. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 205, 1535–1541 (2008).
Article
CAS
PubMed
PubMed Central
Google Scholar
Yu, S. et al. Neutralizing antibodies to IL-18 ameliorate experimental autoimmune neuritis by counter-regulation of autoreactive Th1 responses to peripheral myelin antigen. J. Neuropathol. Exp. Neurol. 61, 614–622 (2002).
Article
CAS
PubMed
Google Scholar
Rivera-Correa, J. & Rodriguez, A. Autoantibodies during infectious diseases: Lessons from malaria applied to COVID-19 and other infections. Front. Immunol. 13, 938011 (2022).
Mohkhedkar, M., Venigalla, S. S. K. & Janakiraman, V. Untangling COVID-19 and autoimmunity: Identification of plausible targets suggests multi organ involvement. Mol. Immunol. 137, 105–113 (2021).
Article
CAS
PubMed
PubMed Central
Google Scholar
Moody, R., Wilson, K., Flanagan, K. L., Jaworowski, A. & Plebanski, M. Adaptive immunity and the risk of autoreactivity in COVID-19. Int. J. Mol. Sci. 22, 8965 (2021).
Article
CAS
PubMed
PubMed Central
Google Scholar
Johnson, D. & Jiang, W. Infectious diseases, autoantibodies, and autoimmunity. J. Autoimmun. 137, 102962 (2023).
Article
CAS
PubMed
Google Scholar
Lee, M. H. et al. Neurovascular injury with complement activation and inflammation in COVID-19. Brain J. Neurol. 145, 2555–2568 (2022).
Article
Google Scholar
Pretorius, E. et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc. Diabetol. 20, 172 (2021).
Article
CAS
PubMed
PubMed Central
Google Scholar
Choudhary, S. et al. Modeling SARS-CoV-2: comparative pathology in rhesus macaque and Golden Syrian hamster models. Toxicol. Pathol.
https://doi.org/10.1177/01926233211072767 (2022).
Rutkai, I. et al. Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates. Nat. Commun. 13, 1745 (2022).
Article
ADS
CAS
PubMed
PubMed Central
Google Scholar
Fernández-Castañeda, A. et al. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell 185, 2452–2468.e16 (2022).
Soung, A. L. et al. COVID-19 induces CNS cytokine expression and loss of hippocampal neurogenesis. Brain awac270
https://doi.org/10.1093/brain/awac270 (2022).
Borsini, A. et al. Neurogenesis is disrupted in human hippocampal progenitor cells upon exposure to serum samples from hospitalized COVID-19 patients with neurological symptoms. Mol. Psychiatry 1–13,
https://doi.org/10.1038/s41380-022-01741-1 (2022).
ISARIC4C Comprehensive Clinical Characterisation Collaboration Website.
https://isaric4c.net.
Ellul, M. A. et al. Neurological associations of COVID-19. Lancet Neurol. 19, 767–783 (2020).
Article
CAS
PubMed
PubMed Central
Google Scholar
Michael, B. D. et al. Characteristic cytokine and chemokine profiles in encephalitis of infectious, immune-mediated, and unknown aetiology. PLoS ONE 11, e0146288 (2016).
Article
PubMed
PubMed Central
Google Scholar
Griffiths, M. J. et al. In enterovirus 71 encephalitis with cardio-respiratory compromise, elevated interleukin 1β, interleukin 1 receptor antagonist, and granulocyte colony-stimulating factor levels are markers of poor prognosis. J. Infect. Dis. 206, 881–892 (2012).
Article
CAS
PubMed
Google Scholar
Michael, B. D. et al. Post-acute serum eosinophil and neutrophil-associated cytokine/chemokine profile can distinguish between patients with neuromyelitis optica and multiple sclerosis; and identifies potential pathophysiological mechanisms—a pilot study. Cytokine 64, 90–96 (2013).
Article
CAS
PubMed
Google Scholar
Needham, E. J. et al. Complex autoantibody responses occur following moderate to severe traumatic brain injury. J. Immunol. 207, 90–100 (2021).
Article
CAS
PubMed
Google Scholar
Ances, B. M. et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 128, 1764–1777 (2005).
Article
PubMed
Google Scholar
Lai, M. et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 9, 776–785 (2010).
Article
CAS
PubMed
PubMed Central
Google Scholar
Irani, S. R. et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 133, 2734–2748 (2010).
Article
PubMed
PubMed Central
Google Scholar
Uy, C. E. et al. Detection and significance of neuronal autoantibodies in patients with meningoencephalitis in Vientiane, Lao PDR. Trans. R. Soc. Trop. Med. Hyg. 116, 959–965 (2022).
Article
CAS
PubMed
PubMed Central
Google Scholar
Irani, S. R. et al. N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 133, 1655–1667 (2010).
Article
PubMed
PubMed Central
Google Scholar
Masi, A. et al. Cytokine levels and associations with symptom severity in male and female children with autism spectrum disorder. Mol. Autism 8, 63 (2017).
Article
PubMed
PubMed Central
Google Scholar
Download references
Acknowledgements
We thank the patients and their loved ones who volunteered to contribute to these studies at one of the most difficult times in their lives, and the research staff in every hospital who recruited patients at personal risk under challenging conditions. This research was funded by the National Institute for Health and Care Research (NIHR) (CO-CIN-01) and jointly by NIHR and UK Research and Innovation (CV220-169, MC_PC_19059). B.D.M. is supported by the UKRI/MRC (MR/V03605X/1), the MRC/UKRI (MR/V007181/1), MRC (MR/T028750/1) and Wellcome (ISSF201902/3). C.D. is supported by MRC (MC_PC_19044). We would like to thank the University of Liverpool GCP laboratory facility team for Luminex assistance and the Liverpool University Biobank team for all their help, especially Dr. Victoria Shaw, Lara Lavelle-Langham, and Sue Holden. We would like to acknowledge the Liverpool Experimental Cancer Medicine Centre for providing infrastructure support for this research (Grant Reference: C18616/A25153). We acknowledge the Liverpool Centre for Cell Imaging (CCI) for provision of imaging equipment (Dragonfly confocal microscope) and excellent technical assistance (BBSRC grant number BB/R01390X/1). Tom Solomon is supported by The Pandemic Institute and the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool. D.K.M. and E.N. are supported by the NIHR Cambridge Biomedical Centre and by NIHR funding to the NIHR BioResource (RG94028 and RG85445), and by funding from Brain Research UK 201819-20. We thank NIHR BioResource volunteers for their participation, and gratefully acknowledge NIHR BioResource centres, NHS Trusts and staff for their contribution. We thank the National Institute for Health and Care Research, NHS Blood and Transplant, and Health Data Research UK as part of the Digital Innovation Hub Programme. Support for title page creation and format was provided by AuthorArranger, a tool developed at the National Cancer Institute. The authors would like to acknowledge the eDRIS team (Public Health Scotland) for their support in obtaining approvals, the provisioning and linking of data and facilitating access to the National Safe Haven. The views expressed are those of the author(s) and not necessarily those of the UKRI, NHS, the NIHR or the Department of Health and Social Care.
Author information
Author notes
These authors contributed equally: Benedict D. Michael, Cordelia Dunai.
These authors jointly supervised this work: Leonie S. Taams, David K. Menon.
Authors and Affiliations
Clinical Infection, Microbiology, and Immunology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, L69 7BE, UK
Benedict D. Michael, Cordelia Dunai, Yun Huang, Sarah A. Boardman, Greta K. Wood, Ceryce Collie, Mark A. Ellul, Geraint Sunderland, Claire Hetherington, Franklyn N. Egbe, Michael Griffiths, Tom Solomon & Malcolm G. Semple
NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool, Liverpool, L69 7BE, UK
Benedict D. Michael, Cordelia Dunai, Tom Solomon & Malcolm G. Semple
The Walton Centre NHS Foundation Trust, Liverpool, L9 7BB, UK
Benedict D. Michael, Mark A. Ellul & Tom Solomon
Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0QQ, UK
Edward J. Needham, Alasdair J. Coles & Patrick F. Chinnery
Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK
Edward J. Needham, Richard Digby, Alexander Ren, Emma Norton, Maya Leibowitz, Soraya Ebrahimi & David K. Menon
Health Data Science, Institute of Population Health, University of Liverpool, Liverpool, L69 3GF, UK
Kukatharmini Tharmaratnam
Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU, UK
Robyn Williams, Andrew Fower, Hannah Fox & Sarosh R. Irani
Departments of Neurology and Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA
Robyn Williams & Sarosh R. Irani
University of Liverpool, Liverpool, L69 7BE, UK
Jordan J. Clark
Department of Microbiology, Icahn School of Medicine, Mount Sinai, NY, 10029, USA
Jordan J. Clark
Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine, Mount Sinai, NY, 10029, USA
Jordan J. Clark
Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, L3 5RF, UK
Parul Sharma, Krishanthi Subramaniam & James P. Stewart
Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, SE5 8AF, UK
Esteban Tato, Alish Palmos & Gerome Breen
NIHR Maudsley Biomedical Research Centre, King’s College London, London, SE5 8AF, UK
Esteban Tato, Alish Palmos & Gerome Breen
Centre for Cell Imaging, Liverpool Shared Research Facilities, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, L69 7ZB, UK
Marie Held
NIHR BioResource, Cambridge University Hospitals NHS Foundation, Cambridge, CB2 0QQ, UK
Kathy Stirrups, Nathalie Kingston, John R. Bradley & Patrick F. Chinnery
Department of Haematology, University of Cambridge, Cambridge, CB2 0QQ, UK
Kathy Stirrups
Clinical Neurosciences, Clinical and Experimental Science, Faculty of Medicine, University of Southampton, Southampton, SO17 1BF, UK
Alexander Grundmann
Department of Neurology, Wessex Neurological Centre, University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, UK
Alexander Grundmann
Département de médecine interne des spécialités (DEMED), University of Geneva, Geneva, CH-1211, Switzerland
Anne-Cecile Chiollaz & Jean-Charles Sanchez
The Pandemic Institute, Liverpool, L7 3FA, UK
Tom Solomon
University of Cambridge, Cambridge, CB2 0QQ, UK
Nathalie Kingston
Department of Medicine, School of Clinical Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK
John R. Bradley
Centre for Immunology, School of Infection & Immunity, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, G12 8TA, UK
Jonathan Cavanagh
Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU, UK
Angela Vincent
Roslin Institute, University of Edinburgh, Edinburgh, EH25 9RG, UK
J. Kenneth Baillie
Intensive Care Unit, Royal Infirmary of Edinburgh, Edinburgh, EH10 5HF, UK
J. Kenneth Baillie
National Heart and Lung Institute, Imperial College London, London, SW7 2BX, UK
Peter J. Openshaw
Imperial College Healthcare NHS Trust, London, W2 1NY, UK
Peter J. Openshaw
Respiratory Unit, Alder Hey Children’s Hospital NHS Foundation Trust, Liverpool, L14 5AB, UK
Malcolm G. Semple
Centre for Inflammation Biology and Cancer Immunology, King’s College London, London, SE1 9RT, UK
Leonie S. Taams
University of Edinburgh, Edinburgh, UK
J. Kenneth Baillie, Beatrice Alex, Benjamin Bach, Debby Bogaert, Annemarie B. Docherty, Ewen M. Harrison, Andrew Law, Alison M. Meynert, Andrew Rambaut, Clark D. Russell, Olivia V. Swann, Thomas M. Drake, Cameron J. Fairfield, Stephen R. Knight, Kenneth A. Mclean, Derek Murphy, Lisa Norman, Riinu Pius, Catherine A. Shaw, Sara Clohisey, Ross Hendry, Lucy Norris, James Scott-Brown, Murray Wham, Wilna Oosthuyzen, Andrew M. McIntosh, David P. Breen, Peter M. Fernandes & Scott Semple
Imperial College London, London, UK
Peter J. Openshaw, Petros Andrikopoulos, Wendy S. Barclay, Kanta Chechi, Graham S. Cooke, Gonçalo dos Santos, Marc-Emmanuel Dumas, Julian L. Griffin, Matthew R. Lewis, Sonia Liggi, Lynn Maslen, Michael Olanipekun, Anthonia Osagie, Vanessa Sancho-Shimizu, Caroline J. Sands, Shiranee Sriskandan, Zoltan Takats, Panteleimon Takis, Ryan S. Thwaites, Adam Hampshire & Nicholas Davies
University of Liverpool, Liverpool, UK
Malcolm G. Semple, William Greenhalf, Karl Holden, Saye Khoo, Shona C. Moore, Carlo Palmieri, William A. Paxton, Georgios Pollakis, Tom Solomon, Lance C. Turtle, Marie Connor, Jo Dalton, Carrol Gamble, Michelle Girvan, Sophie Halpin, Janet Harrison, Clare Jackson, Laura Marsh, Stephanie Roberts, Egle Saviciute, Victoria Shaw, Cara Donegan, Rebecca G. Spencer, Chloe Donohue, Hayley Hardwick, Alastair Darby, Arina Tamborska, Ava Easton, Benedict D. Michael, Bethany Facer, Bhagteshwar Singh, Brendan Sargent, Ceryce Collie, Charles Leek, Cordelia Dunai, Eva M. Hodel, Greta K. Wood, C. Hannah, Julian Hiscox, Merna Samuel, Michael Griffiths, Shahd H. Hamid, Simon Keller, Sophie Pendered & Victoria Grimbly
Public Health England, London, UK
Meera Chand, Jake Dunning, Samreen Ijaz, Richard S. Tedder & Maria Zambon
MRC-University of Glasgow Centre for Virus Research, Glasgow, UK
Ana da Silva, Antonia Y. Wai, Massimo Palmarini, David L. Robertson, Janet T. Scott, Emma C. Thomson & Sarah E. McDonald
University of Sheffield, Sheffield, UK
Thushan de Silva, A. A. R. Thompson, Annalena Venneri, Pamela J. Shaw & Thomas M. Jenkins
Liverpool School of Tropical Medicine, Liverpool, UK
Tom Fletcher & Sylviane Defres
University of Birmingham, Birmingham, UK
Christoper A. Green, Matthew R. Broome & Tonny Veenith
University College London, London, UK
Rishi K. Gupta, Mahdad Noursadeghi, Anthony S. David, Judith Breuer, Laura Benjamin, Michael P. Lunn, Michael S. Zandi & Nicholas Wood
University of Oxford, Oxford, UK
Peter W. Horby, Paul Klenerman, Laura Merson, Louise Sigfrid, David Stuart, James Lee, Daniel Plotkin, Gail Carson, Angela Vincent, Eugene Duff, Karla Miller, Masud Husain, Paul J. Harrison, Peter Jezzard, Sarosh Irani & Stephen Smith
Nottingham University Hospitals NHS Trust, Nottingham, UK
Wei S. Lim
John Radcliffe Hospital, Oxford, UK
Alexander J. Mentzer
King’s College London, London, UK
Nicholas Price, Marlies Ostermann, Akshay Nair, Alex Dregan, Alish Palmos, Ammar Al-Chalabi, Daniel J. van, Dina Monssen, Fernando Zelaya, Gerome Breen, Henry C. Rogers, Jonathan R. Coleman, Kiran Glen, Leonie Taams, Lily George, Matthew Butler, Matthew Hotopf, Naomi Martin, Rahul Batra, Silvia Rota, Steven Williams, Sui H. Wong, Thomas Pollak & Timothy Nicholson
University of Cambridge, Cambridge, UK
Charlotte Summers, Alaisdair Coles, Angela Roberts, David K. Menon, David M. Christmas, Edward Bullmore, Edward Needham, Ewan Harrison, Guy B. Williams, John R. Bradley, Richard Bethlehem, Sharon Peacock, Stephen J. Sawcer & Virginia Newcombe
Public Health Scotland, Edinburgh, UK
Susan Knight & Sarah Tait
ISARIC4C Investigators, Liverpool, UK
Eva Lahnsteiner, Richard Clark, Audrey Coutts, Lorna Donnelly, Angie Fawkes, Tammy Gilchrist, Katarzyna Hafezi, Louise MacGillivray, Alan Maclean, Sarah McCafferty, Kirstie Morrice, Lee Murphy, Nicola Wrobel, Kayode Adeniji, Daniel Agranoff, Ken Agwuh, Dhiraj Ail, Erin L. Aldera, Ana Alegria, Sam Allen, Brian Angus, Abdul Ashish, Dougal Atkinson, Shahedal Bari, Gavin Barlow, Stella Barnass, Nicholas Barrett, Christopher Bassford, Sneha Basude, David Baxter, Michael Beadsworth, Jolanta Bernatoniene, John Berridge, Colin Berry, Nicola Best, Pieter Bothma, Robin Brittain-Long, Naomi Bulteel, Tom Burden, Andrew Burtenshaw, Vikki Caruth, David Chadwick, Duncan Chambler, Nigel Chee, Jenny Child, Srikanth Chukkambotla, Tom Clark, Paul Collini, Catherine Cosgrove, Jason Cupitt, Maria-Teresa Cutino-Moguel, Paul Dark, Chris Dawson, Samir Dervisevic, Phil Donnison, Sam Douthwaite, Andrew Drummond, Ingrid DuRand, Ahilanadan Dushianthan, Tristan Dyer, Cariad Evans, Chi Eziefula, Chrisopher Fegan, Adam Finn, Duncan Fullerton, Sanjeev Garg, Atul Garg, Effrossyni Gkrania-Klotsas, Jo Godden, Arthur Goldsmith, Clive Graham, Elaine Hardy, Stuart Hartshorn, Daniel Harvey, Peter Havalda, Daniel B. Hawcutt, Maria Hobrok, Luke Hodgson, Anil Hormis, Joanne Howard, Michael Jacobs, Susan Jain, Paul Jennings, Agilan Kaliappan, Vidya Kasipandian, Stephen Kegg, Michael Kelsey, Jason Kendall, Caroline Kerrison, Ian Kerslake, Oliver Koch, Gouri Koduri, George Koshy, Shondipon Laha, Steven Laird, Susan Larkin, Tamas Leiner, Patrick Lillie, James Limb, Vanessa Linnett, Jeff Little, Mark Lyttle, Michael MacMahon, Emily MacNaughton, Ravish Mankregod, Huw Masson, Elijah Matovu, Katherine McCullough, Ruth McEwen, Manjula Meda, Gary Mills, Jane Minton, Kavya Mohandas, Quen Mok, James Moon, Elinoor Moore, Patrick Morgan, Craig Morris, Katherine Mortimore, Samuel Moses, Mbiye Mpenge, Rohinton Mulla, Michael Murphy, Thapas Nagarajan, Megan Nagel, Mark Nelson, Lillian Norris, Matthew K. O’Shea, Igor Otahal, Mark Pais, Selva Panchatsharam, Danai Papakonstantinou, Padmasayee Papineni, Hassan Paraiso, Brij Patel, Natalie Pattison, Justin Pepperell, Mark Peters, Mandeep Phull, Stefania Pintus, Tim Planche, Frank Post, David Price, Rachel Prout, Nikolas Rae, Henrik Reschreiter, Tim Reynolds, Neil Richardson, Mark Roberts, Devender Roberts, Alistair Rose, Guy Rousseau, Bobby Ruge, Brendan Ryan, Taranprit Saluja, Matthias L. Schmid, Aarti Shah, Manu Shankar-Hari, Prad Shanmuga, Anil Sharma, Anna Shawcross, Jagtur S. Pooni, Jeremy Sizer, Richard Smith, Catherine Snelson, Nick Spittle, Nikki Staines, Tom Stambach, Richard Stewart, Pradeep Subudhi, Tamas Szakmany, Kate Tatham, Jo Thomas, Chris Thompson, Robert Thompson, Ascanio Tridente, Darell Tupper-Carey, Mary Twagira, Nick Vallotton, Rama Vancheeswaran, Rachel Vincent, Lisa Vincent-Smith, Shico Visuvanathan, Alan Vuylsteke, Sam Waddy, Rachel Wake, Andrew Walden, Ingeborg Welters, Tony Whitehouse, Paul Whittaker, Ashley Whittington, Meme Wijesinghe, Martin Williams, Lawrence Wilson, Stephen Winchester, Martin Wiselka, Adam Wolverson, Daniel G. Wootton, Andrew Workman, Bryan Yates, Peter Young, Katie A. Ahmed, Jane A. Armstrong, Milton Ashworth, Innocent G. Asiimwe, Siddharth Bakshi, Samantha L. Barlow, Laura Booth, Benjamin Brennan, Katie Bullock, Nicola Carlucci, Emily Cass, Benjamin W. Catterall, Jordan J. Clark, Emily A. Clarke, Sarah Cole, Louise Cooper, Helen Cox, Christopher Davis, Oslem Dincarslan, Alejandra D. Carracedo, Chris Dunn, Philip Dyer, Angela Elliott, Anthony Evans, Lorna Finch, Lewis W. Fisher, Lisa Flaherty, Terry Foster, Isabel Garcia-Dorival, Philip Gunning, Catherine Hartley, Anthony Holmes, Rebecca L. Jensen, Christopher B. Jones, Trevor R. Jones, Shadia Khandaker, Katharine King, Robyn T. Kiy, Chrysa Koukorava, Annette Lake, Suzannah Lant, Diane Latawiec, Lara Lavelle-Langham, Daniella Lefteri, Lauren Lett, Lucia A. Livoti, Maria Mancini, Hannah Massey, Nicole Maziere, Sarah McDonald, Laurence McEvoy, John McLauchlan, Soeren Metelmann, Nahida S. Miah, Joanna Middleton, Joyce Mitchell, Ellen G. Murphy, Rebekah Penrice-Randal, Jack Pilgrim, Tessa Prince, Will Reynolds, P. M. Ridley, Debby Sales, Victoria E. Shaw, Rebecca K. Shears, Benjamin Small, Krishanthi S. Subramaniam, Agnieska Szemiel, Aislynn Taggart, Jolanta Tanianis-Hughes, Jordan Thomas, Erwan Trochu, Libby v. Tonder, Eve Wilcock & J. E. Zhang
University of Manchester, Manchester, UK
Gary Leeming, Craig J. Smith & Katherine C. Dodd
King’s College Hospital, London, UK
Tassos Grammatikopoulos
Royal Infirmary Edinburgh, Edinburgh, UK
Seán Keating
Roslin Institute, Edinburgh, UK
Fiona Griffiths
COVID-CNS Consortium, York, UK
Adam Sieradzki
Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
Adam W. Seed
University of Nottingham, Nottingham, UK
Afagh Garjani, Christopher M. Allen & Nikos Evangelou
Edinburgh University, Edinburgh, UK
Alan Carson
University of Southampton, Southampton, UK
Alexander Grundmann, Jay Amin & Marc Hardwick
Nottingham University Hospital, Nottingham, UK
Angela E. Holland
University of Glasgow, Glasgow, UK
Arvind Patel, Emma Thomson, Jonathan Cavanagh & Neil Basu
Salford Royal Foundation Trust, Manchester, UK
Bethan Blackledge & Jade D. Harris
Queens University Belfast, Belfast, UK
Cherie Armour, Ciaran Mulholland, Claire L. MacIver, Emily McGlinchey & Ryan McIlwaine
Newcastle University, Newcastle, UK
Christopher M. Morris, David Cousins, John-Paul Taylor, Mark R. Baker & Stella-Maria Paddick
Cardiff University, Cardiff, UK
John P. Aggleton, Jonathan Underwood, Neil A. Harrison & Neil Harrison
Sheffield Institute for Translational Neuroscience, Sheffield, UK
Daniel Madarshahian
Dundee University, Dundee, UK
David Christmas
South London and Maudsley NHS Foundation Trust, London, UK
Gabriella Lewis
Belfast Health and Social Care Trust, Belfast, UK
Gavin McDonnell & Stella Hughes
COVID-CNS Consortium, Edinburgh, UK
Jacqueline Smith
The University of Manchester, Manchester, UK
James B. Lilleker
Kings College London, London, UK
Monika Hartmann
Royal Infirmary of Edinburgh, Edinburgh, UK
Nadine Cossette
Aintree University Hospital, Liverpool, UK
Nathalie Nicholas
National Institute for Health Research (NIHR) Bioresource, London, UK
Parisa Mansoori
Birmingham University, Birmingham, UK
Rachel Upthegrove & Thomas Jackson
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
Rebecca Gregory
Translational and Clinical Research, Newcastle, UK
Rhys H. Thomas
The Stroke Association, London, UK
Richard Francis
The University of Sheffield, Sheffield, UK
Ronan O’Malley
The University of Edinburgh, Edinburgh, UK
Rustam A. Salman
Institute of Mental health, Nottingham, UK
Sandar Kyaw
Royal Stoke University Hospital, Stoke on Trent, UK
Savini Gunatilake
Northern Health and Social Care Trust, Belfast, UK
Suzanne Barrett
Consortia
ISARIC4C Investigators
Author
Topic: Die Causa Christoph Kleinschnitz: Dubiose Studien hetzen gegen LongCovid-Kranke (Read 688 times)